Amplification and overexpression of the miR-17-92 microRNAs (miRNA) cluster at 13q31.3 has recently reported, with pointers to functional involvement in the development of B-cell lymphomas and lung cancers. In the present study, we show that inhibition of miR-17-5p and miR-20a with antisense oligonucleotides (ONs) can induce apoptosis selectively in lung cancer cells overexpressing miR-17-92, suggesting the possibility of 'OncomiR addiction' to expression of these miRNAs in a subset of lung cancers. In marked contrast, antisense ONs against miR18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth, showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth. During the course of this study, we also found that enforced expression of a genomic region, termed C2, residing 3 0 to miR-17-92 in the intron 3 of C13orf25 led to marked growth inhibition in association with double stranded RNA-dependent protein kinase activation. Finally, this study also revealed that the vast majority of C13orf25 transcripts are detected as Drosha-processed cleavage products on Northern blot analysis and that a novel polyadenylation site is present 3 0 to the miR-17-92 cluster and 5 0 to the C2 region. Taken together, the present findings contribute towards better understanding of the oncogenic roles of miR-17-92, which might ultimately lead to the future translation into clinical applications.
Introduction
MicroRNAs (miRNAs), which encode small non-coding RNAs of approximately 22 nucleotides (nt), are now recognized as a very large gene family present throughout the genomes of plants and metazoans (Ambros, 2004; Bartel, 2004; Zamore and Haley, 2005) . Evolutionally conserved miRNAs all have stem-loop structures and are often found as clustered sequences. Mature miRNAs processed by two-step cleavage involving Drosha and Dicer are thought to regulate negatively expression of a large number of genes carrying target sites within 3 0 untranslated regions, whereas rapidly accumulating evidence points to miRNA utilization of multiple molecular mechanisms for gene silencing. Although the developmental and physiological roles of each miRNA in man remain to be elucidated in detail, it is to note that recent studies have clearly shown the presence of miRNA alterations in various human cancers, suggesting potential roles in the multistep processes of carcinogenesis and disease progression (Esquela-Kerscher and Slack, 2006) .
We previously reported that family members of an archetypical miRNA, let-7, are frequently downregulated in lung cancers in association with shortened postoperative survival, and that enforced expression of let-7 modestly reduced lung cancer cell growth, suggesting an involvement in lung cancer development (Takamizawa et al., 2004) . This notion was further substantiated by the subsequent identification of RAS as a target gene for let-7 (Johnson et al., 2005) . Amplification and overexpression of the miR-17-92 miRNA cluster at 13q31.3 was recently reported in B-cell lymphomas (Ota et al., 2004; He et al., 2005) and lung cancers (Hayashita et al., 2005) . Enforced expression of this polycistronic miRNA cluster could accelerate B-cell lymphoma development in Em-Myc transgenic mice by reducing apoptosis (He et al., 2005) , whereas the introduction of the miR-17-92 cluster, but not the putative open reading frame (ORF) of the C13orf25 gene encompassing miR-17-92, enhanced lung cancer cell growth, lending further credence to the involvement of such highly conserved miRNAs rather than the short non-conserved ORF of C13orf25 (Hayashita et al., 2005) . In addition, it has been shown that expression of the miR-17-92 cluster is directly regulated by c-myc, whereas E2F1, a direct downstream target for c-myc, is in turn negatively regulated by two components of this miRNA cluster, miR-17-5p and miR-20a, emphasizing the complexity of regulatory circuits of gene expression involving miRNAs (O'Donnell et al., 2005) .
Thus, considerable evidence for involvement of overexpression of the miR-17-92 miRNA cluster in the development of lymphomas and lung cancers has accumulated, but there remain several intriguing unresolved questions. In this study, we therefore investigated whether it is possible to inhibit lung cancer cell growth by downregulating any of the miRNAs within the miR-17-92 cluster. In addition, we also characterized C13orf25 transcripts in relation to processing and the resultant products in a systematic manner. Northern blot analysis of miR-17-5p and miR-20a showing significant inhibition of miR-17-5p and miR-20a by the antisense ONs. Considerable cross-inhibition is apparent between them, whereas either let-7 or other miRNAs of the miR-17-92 cluster including miR-18a, miR-19a and miR-92-1 in (b), are not inhibited, which is consistent with the levels of sequence similarities among miRNAs of the miR-17-92 cluster. (c) Northern blot analysis showing significant inhibition of miR-18a, miR-19a and miR-92-1 by their corresponding antisense ON treatments. A human lung cancer cell line, Calu6 overexpressing miR-17-92 (Hayashita et al., 2005) , was cultured with RPMI 1640/5% FCS at 371C with 5% CO 2 as previously described (Maeno et al., 2006) . Cells were plated at 1 Â 10 6 in 10 cm dishes on day 1, and each ON was transfected at 10 nM with Lipofectamine 2000 (Invitrogen) on day 2. Transfected cells were split into two in the same sized dishes on day 3. After second round transfection on day 4, cells were grown in fresh media and harvested on day 6. For Northern blot analysis of mature miRNAs, RNA samples were prepared with the acid-phenol extraction procedure, and 10 mg of each was applied to 15% polyacrylamide gels as described previously (Takamizawa et al., 2004) . Antisense ONs as well as the respective scrambled ONs were synthesized as hybrid molecules between deoxyribonucleotides and 2 0 -O, 4 0 -C-methylene bridge (locked nucleic acid, LNA) modification of all G and C residues (Greiner, Tokyo, Japan) and their nucleotide sequences are given in Supplementary , were plated at 8 Â 10 4 per well in 6-well plates on day 1, and ONs were transfected on day 2 at the indicated final concentrations (5-20 nM) with Lipofectamine 2000. Cells in each well were divided into four and plated in 24-well plates on day 3 and transfected again with the same ONs on day 4. Culture media were replaced on day 5, and viable cell numbers were measured with TetraColor One (Seikagaku, Tokyo, Japan) on day 6. Three independent experiments were performed for miR-17-5p and miR-20a, whereas two independent experiments were conducted for miR-18a, miR-19a and miR-92-1. FACS analysis (c): Cells were plated at 1 Â 10 5 per well in 6-well plate on the first day (day 1), and transfected in triplicate on day 2 with ON at 10 nM each with Lipofectamine 2000, followed by re-plating into 12-well plates on day 3. After second round of transfection on day 4, cells were grown in fresh media. Cells were lysed on day 5 with 0.5% NP-40, and cell nuclei were stained with propidium iodide (Sigma, St Louis, MO, USA). Cellular DNA contents were measured using a FACScalibur flow cytometer equipped with the CELLQuest program (BD Biosciences, San Jose, CA, USA) in duplicate in three independent experiments. TUNEL assay (c): Cells grown at 3 Â 10 5 in 6-well dishes were transfected with ONs on day 2 as described for FACS analysis, and then split into 10 on cover slips on day 3. After the second transfection on day 4, cells were stained using an in situ cell death detection kit (Roche Diagnostics, Indianapolis, IN, USA) on day 5.
Results

Growth inhibition with antisense oligonucleotides (ONs) against miR-17-5p and miR-20a
We first investigated which miRNAs within the miR-17-92 cluster could be possible therapeutic targets to inhibit cancer cell growth. Antisense ONs incorporating LNA (Gleave and Monia, 2005) at all guanine and cytosine residues were used to downregulate miR-17-5p, miR-18a, miR-19a, miR-20a and miR-92-1. Northern blot analysis showed marked cross-inhibition between miR-17-5p and miR-20a owing to their highly homologous nature (Figure 1a) , however, the same antisense treatment did not result in any reduction in expression of miR-18a, miR-19a, miR-92-1 and let-7, confirming specificity of the antisense treatment (Figure 1b) . Antisense ONs against miR-18a, miR-19a and miR-92-1 clearly inhibited their corresponding miRNAs (Figure 1c ). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays revealed significant reduction of cell growth on transfection of antisense ONs against miR-17-5p and miR-20a in human cancer cell lines with abundant miR-17-92 expression, including Calu6 and ACC-LC-172 (Figure 2a ), whereas we did not observe any noticeable inhibition by such treatment in A549 cells expressing low levels of these miRNAs (Figure 2a ). In contrast, antisense ONs against miR-18a and miR-19a did not exhibit such inhibitory effects, whereas inhibition of miR-92-1 resulted in only modest reduction of cell growth (Figure 2b) , showing significant distinctions among miRNAs of the miR-17-92 cluster in terms of their roles in cancer cell growth. Terminal transferase dUTP nick end labeling (TUNEL) assays were then performed to examine whether apoptosis was induced by the treatment with antisense ONs against miR-17-5p and miR-20a, either alone or in combination, in Calu6 cells overexpressing miR-17-92 (Figure 2c ). Significant induction of TUNEL-positive apoptotic cells by the treatment was indeed observed, and it was further confirmed by fluorescence activated cell sorter (FACS) analysis, showing marked increase in the proportions of sub-G1 populations (Figure 2c ).
Identification of a growth inhibitory region adjacent to miR-17-92
During the course of characterization of C13orf25 transcripts carrying miR-17-92, we observed quite marked growth suppression when either the entire intron 3 containing the miR-17-92 miRNA cluster or the 3 0 half of intron 3 was introduced into A549 with very low expression of miR-17-92, whereas the growth of PC1 cells overexpressing miR-17-92 (Hayashita et al., 2005) was not affected (Figure 3a and b) . Interestingly, we noted that activating phosphorylation of doublestranded RNA-dependent protein kinase (PKR) was induced only in A549, but not in PC1 by the forced expression of 3 0 half of intron 3 (Figure 3c) , showing a clear difference in PKR activation in lung cancer cell lines with and without miR-17-92 overexpression. As close inspection of the 3 0 half of intron 3 revealed the existence of three modestly conserved regions between human and mouse forms at 56% identity for C1, 63% for C2, 55% for C3 of intron 3 and 53% C3 of exon 4, we examined whether any of these might specifically have inhibitory activity in A549. Consequently, conserved region 2 (C2) was found to be responsible, possibly in part by activating PKR (Figure 3d ) and consequential proteolytic activation of caspase-7 ( Supplementary  Figure 1) (Gil and Esteban, 2000) .
Characterization of C13orf25 transcripts
We conducted 3 0 RACE analysis to search for additional as yet unidentified transcripts, which might terminate 5 0 to the inhibitory region of intron 3. Our 3 0 RACE experiment using polymerase chain reaction (PCR) primers 5 0 to the post-miR probe yielded two distinct bands, one of which turned out to be owing to illegitimate priming from a stretch of 27 adenines between the C1 and C2 regions. Sequencing of the other band clearly indicated the existence of novel transcripts utilizing a common attaaa polyadenylation signal (Zarudnaya et al., 2003) , 85 bp 3 0 to the 3 0 end of the miR-17-92 cluster, which harbor miR-17-92 but not the C2 region (Figure 4a ). 0 inhibitory region of intron 3, confining the growth-inhibitory and PKR-activating segment to the C2 region. Fragments of C13orf25 were PCR-amplified and cloned into a modified pcDNA3 vector (Invitrogen, Carlsbad, CA, USA) carrying a puromycin resistance gene. Information on nucleotide sequences of the cloned fragments is given in Supplementary Table 2. Each expression vector (0.8 mg) carrying various C13orf25 fragments was transfected in triplicate in three independent experiments into 3 Â 10 5 cells grown in 6-well plates using Lipofectamine 2000, and selected with puromycin (2 mg/ml for 2 days and 0.5 mg/ml thereafter for A549 and 0.5 mg/ml for PC1). Ten days after transfection, cell proliferation was measured with TetraColor One, and was expressed as % control (empty vector). Luciferase reporter activity was also measured as a reflection of cell proliferation as described in our previous paper (Hayashita et al., 2005) . In brief, cells grown at 3 Â 10 5 in 6-well dishes were transfected in triplicate with 0.72 mg each of the expression vectors carrying fragments of C13orf25 along with 0.08 mg of pRL-TK reporter expressing Renilla luciferase (Promega, Madison, WI, USA). The day after transfection, each transfected dish was divided into four, and the Renilla luciferase activity was then measured as a reflection of cell numbers coexpressing both the C13orf25 fragments and pRL-TK on the next day using the Dual-Luciferase Reporter Assay System (Promega). Each experiment was independently repeated at least twice. For Western blotting analysis, cells grown at 3 Â 10 5 in 6-well dishes were transfected with 1.0 mg each of the various expression vectors on day 2, harvested on the next day and analysed with anti-phospho-PKR (Th451; Cell Signaling Technology, Danvers, MA, USA). Re-probing with mouse monoclonal anti-a-tubulin (Sigma) antibody was also performed as an internal control.
Northern blot analysis was performed using various probes to characterize C13orf25 transcripts carrying miR-17-92 in detail. We observed the presence of two major bands (2.4 and 1.1 kb; solid and open arrows in Figure 4b ) and several minor bands using a C13orf25 cDNA probe as well as a probe immediately 5 0 to miR-17-92 (Hayashita et al., 2005) . In contrast, probes corresponding to region 167 bp 3 0 to miR-17-92 as well as to the C1 region of intron 3 or exon 4 did not detect these two major transcripts but rather hybridized only with the largest minor transcript (solid arrowhead), which must harbor the C2 region. Analysis using poly(A) þ RNA and the C13orf25 probe detected only the latter largest minor transcript. Therefore, these findings strongly suggested that the former two major and the latter minor bands probably correspond to the 5 0 and 3 0 cleavage products, respectively, resulting from Drosha-mediated processing at the miR-17-92 cluster. An intron 1 probe detected the larger of the two major transcripts as well as a closely spaced minor transcript (open arrowhead), corresponding to those with and without intron 2, as we could verify by reverse transcription-PCR analysis (data not shown). Transcripts containing only the predicted exons were hardly detectable in our Northern blot analysis, and did not correspond to the faint band of presently unknown origin detected with the intron 1 probe (asterisk). The size of the 3 0 cleavage product of the novel transcript identified by the 3 0 RACE analysis may have been too small to detect by Northern blotting.
Discussion
The present findings clearly show that inhibition of miR-17-5p and miR-20a with antisense ONs can induce apoptosis in lung cancer cells overexpressing miR-17-92. As miR-17-5p and miR-20a were previously shown to repress directly E2F1 by binding to target sites in its 3 0 untranslated region (O'Donnell et al., 2005) , induction of apoptosis may also be in part related to the induction of E2F1 owing to relief from inhibition by these miRNAs and subsequent inadvertent cell cycle progression into S phase (Macleod, 1999) . Intricate fine-tuning of gene expression by miRNAs is presumably under differential influence of degrees of homology and numbers of target sites as well as the context of expression profiles of various genes in the cells of interest. Therefore, it is not inconceivable that survival of cancer cells with overexpression of miR-17-92 might depend in part on the fine-tuned miRNAs-mediated balance among E2F1 and their as yet unverified predicted target genes. Although further studies are obviously necessary, a novel cancerspecific treatment strategy could ultimately be established based on the antisense ON-based perturbation of the delicate balance, which seemingly elicits synthetic lethality of cancer cells. In this connection, it is interesting that we observed noticeable inhibition by such treatment in Calu6 and ACC-LC-172 with miR-17-92 overexpression but not in A549 expressing low levels of these miRNAs, suggesting the possible existence of 'OncomiR addiction'.
Enforced expression of the inhibitory C2 region led to marked growth inhibition in association with PKR activation in A549 with low miR-17-92 expression, whereas PC1 overexpressing miR-17-92 did not show any noticeable activation of PKR nor adverse effects on cell growth. It should be stressed that PKR induces apoptosis (Gil and Esteban, 2000) and has been suggested to function as a potential tumor suppressor (Meurs et al., 1993) . As a small proportion of the processed transcripts of C13orf25 is detectable in cytoplasm (Hayashita et al., 2005) , it is possible that the processed fragments containing the inhibitory C2 region might play a role in the subsequent PKR activation in cytoplasm. Further studies are therefore warranted to investigate systematically whether PKR inactivation makes cancer cells permissive with regard to expression of the C2 region, with a role in miR-17-92 overexpression. Although interactions of PKR kinase with specific viral RNAs have been studied in much detail, information about cellular mRNAs is limited (Bommer et al., 2002) . The fact that the three conserved regions are similarly present within 3 kb 3 0 to this miRNA cluster in the mouse genome points to potential evolutionary implications. 0 -RACE (a), polyA þ RNA was isolated with Oligotex-dT30 Super (Nippon Roche Co., Tokyo, Japan) from total RNA of PC1 overexpressing C13orf25 and 3 0 RACE was performed according to the supplier's instructions with a SMARTTM RACE cDNA Amplification Kit (Clontech Takara Bio., Mountain View, CA, USA). Briefly, firststrand cDNA was synthesized with an oligo (dT) primer, and then nested PCR amplifications were conducted using the first (5 0 -GAG AGGCCAGCCATTGGAAGAG) and second (5 0 -GGTGGGG ATTGTGACCAGAAG) forward primers. PCR products were analysed with a CEQ8000 sequencer (Beckman Coulter, Fullerton, CA, USA). Northern blot analysis of C13orf25 expression was performed using 10 mg each of RNA samples prepared with an RNeasy kit (Qiagen, Valencia, CA, USA) by formaldehydeagarose gel electrophoresis as described previously (Hayashita et al., 2005) . PCR-generated probes were prepared using the primer pairs listed in Supplementary Table 3. Our detailed characterization of the C13orf25 transcripts by Northern blot analysis indicated the vast majority of detectable transcripts to be Drosha-processed cleavage products, which seems to be consistent with our previous observation that the C13orf25 transcripts were mainly localized in the nucleus (Hayashita et al., 2005) . In addition, we showed the presence of a novel polyadenylation site located 3 0 to the miR-17-92 cluster and 5 0 to the inhibitory C2 region. Although future studies are necessary to evaluate relative abundance between transcripts with and without utilization of this polyadenylation site, this finding raises the possibility of potential involvement as another mechanism for escaping from the inhibitory effects of the C2 region. It has been suggested that miRNAs are often transcribed by RNA polymerase II as a polycistronic cluster (Cullen, 2004) , but there are very few examples which have been characterized in detail in relation to the genomic organization and the processing of precursor transcripts. Thus, the present study highlights miR-17-92 as a rare such example in the human genome.
In summary, from our finding that antisense ONs inhibiting miR-17-5p and miR-20a effectively elicit apoptosis in cancer cells overexpressing the miR-17-92 miRNA cluster, future studies with the aim of establishing a promising novel means for cancer treatment are clearly warranted (Gleave and Monia, 2005; Krutzfeldt et al., 2005) . Identification of additional target genes for the miR-17-92 cluster will also be important for full understanding of how overexpression of these miRNAs confers selective advantages on cancer cells. In addition, future studies on how the miR-17-92 miRNA cluster confers growth advantage to cancer cells will also be necessary in conjunction with the evaluation of physiological significance of the inhibitory C2 region of intron 3 and the novel transcript terminating 5 0 to C2.
